Key Highlights
- Net loss narrowed to USD 4.0 million from USD 5.8 million a year earlier.
- Research and development expense fell to USD 2.1 million from USD 2.8 million.
- General, administrative and other expense was USD 2.0 million versus USD 2.2 million.
- Cash and equivalents were USD 1.2 million at September 30, 2026.
Lower Spending Narrows the Loss
FibroBiologics, Inc. (NASDAQ:FBLG) reported a third-quarter net loss of USD 4.0 million versus USD 5.8 million, an improvement of USD 1.7 million. The data set lists a loss of USD 0.38 per share against an estimated USD 0.63 loss, and the filing results behind that are summarized here.
Research and development expense was USD 2.1 million versus USD 2.8 million, and general, administrative and other expense was USD 2.0 million versus USD 2.2 million. Total operating expenses were USD 4.1 million versus USD 5.0 million, and the loss from operations matched that figure.
Other Income and Expense
Total other income was USD 23 thousand versus other expense of USD 740 thousand a year earlier. The prior-year quarter carried a USD 846 thousand charge from the change in Fair Value of convertible debt, while the current quarter included a USD 9 thousand change in the fair value of a standby Equity purchase agreement Put Option liability, USD 20 thousand of interest income and USD 4 thousand of interest expense.
The change column in the filing shows Research and Development down USD 714 thousand, general and administrative down USD 253 thousand and total operating expenses down USD 967 thousand, while the net loss improved by USD 1.7 million. Interest income was USD 20 thousand versus USD 73 thousand, reflecting a lower cash balance, and the put option Liability change was USD 9 thousand versus USD 33 thousand.
The company presents its figures in thousands, with net loss of USD 4,048 thousand against USD 5,778 thousand. Its stated programs span wound healing, psoriasis, multiple sclerosis, degenerative disc disease and certain cancers, in addition to a thymic organoid concept aimed at reversing thymic involution. The filing says the funding plans management has put in place are not sufficient on their own to remove the Going Concern doubt, which keeps the cash balance and the standby equity Facility in focus.
Clinical Focus and Liquidity
The company describes itself as a clinical-stage biotechnology company developing "fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs", with programs in wound healing, psoriasis, multiple sclerosis and degenerative disc disease and a thymic organoid concept for longevity applications.
Cash and cash equivalents were USD 1.2 million at September 30, 2026. The filing states that management's plans to obtain additional funding are not sufficient to alleviate substantial doubt about the company's ability to continue as a going concern.
Items to Follow
Reference points include research spending as programs progress, the use of the standby equity purchase agreement, general and administrative costs and the cash position described against the going concern disclosure.






Please wait processing your request...